Physiologically based PK modeling are the deal-breakers. Born in the 70s, they are now living their heyday. New dose proposals based on more accurate physiology; target concentration prediction; hypothesis testing; DDI, transporter dynamics, alternative route of absorptions; new formulations; pediatric/geriatric dosing; These are just a few examples of PBPK usage and inclusion in NDAs. We master PBPK building and analysis. The way we see it, PBPK has become the tool to smooth your drug development transition. It is cheap and powerful, and increasingly welcomed by Regulators.